EUVIMEDScopri EUVIMED
Open access · CC BY-NC 4.0

Long‐term hematopoietic dysfunction in patients with large‐scale mitochondrial DNA deletion syndromes

Noa Greenberg-Kushnir iD, Liron D Grossmann iD, Assaf Arie Barg iD, Ginnete Schiby, Corine Mardoukh, Nira Varda-Bloom, Victoria Marcu-Malina, Yair Anikster, Noah Gruber, Einat Lahav, Yoav Bolkier, Diana Bar and 3 more

Pediatric Blood & Cancer · 2025

DOI: 10.1002/pbc.31383 ↗

At a glance

Journal article in Pediatric Blood & Cancer, 2025. Written by Noa Greenberg-Kushnir and 14 co-authors. Institution: Division of Pediatric Hematology and Oncology, The Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel Hashomer, Israel. Major MEDLINE topics: Lipid Metabolism, Inborn Errors, Acyl-CoA Dehydrogenase, Long-Chain, DNA, Mitochondrial, Congenital Bone Marrow Failure Syndromes. 25 references. The full text is freely available (open access, CC BY-NC 4.0).

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Background

Pearson syndrome (PS) and Kearns‐Sayre syndrome (KSS) are single large‐scale mitochondrial DNA deletion (SLSMD) syndromes. PS is characterized by severe, transient childhood cytopenia, whereas KSS typically manifests later in life without hematologic abnormalities. Despite distinct clinical presentations, both share a common mitochondrial DNA deletion. Recent observations suggest a potential link between PS progression and myeloid malignancy development, indicating that bone marrow failure (BMF) may be a key aspect of PS pathology and potentially universal across SLSMDs.

Methods

This study explores longitudinal hematological manifestations of SLSMD syndromes, focusing on bone marrow (BM) dysfunction.

Results

Sixteen patients with SLSMDs (13 PS and 3 KSS) were followed, of whom 75% experienced cytopenia, necessitating blood transfusions in 56%. Despite achieving transfusion independence at a median age of 24 months, persistent hematological abnormalities were noted. Comprehensive longitudinal BM studies were conducted in 62% of subjects and consistently revealed signs of marrow dysfunction, even without concurrent cytopenia. Median BM cellularity at a median age of four years and eight months was 50%, with histological signs of dyserythropoiesis, abnormal megakaryocytes, and signs suggesting myelodysplasia. Reduced CD34 + counts and BM colony‐forming unit capacity were noted, alongside chromosome 7 aberrations in 16% of patients on cytogenetic studies.

Conclusions

Our findings establish BM dysfunction as a persistent hallmark of SLSMD syndromes, posing a risk of clonal evolution and acquisition of chromosome 7 aberrations. This aligns with recent literature, emphasizing enduring BMF in SLSMD syndromes and advocating for tailored hematological monitoring guidelines for this unique patient cohort.

Subjects

MeSH terms (MEDLINE)

Lipid Metabolism, Inborn ErrorsAcyl-CoA Dehydrogenase, Long-ChainDNA, MitochondrialCongenital Bone Marrow Failure SyndromesKearns-Sayre SyndromeMitochondrial DiseasesHumansMaleFemaleChildChild, PreschoolInfantAdolescentFollow-Up StudiesMuscular DiseasesLongitudinal StudiesBone Marrow Failure Disorders

Author keywords

Hematopoietic dysfunctionKearns‐Sayre syndromePearson syndromemonosomy 7myelodysplasiasingle large‐scale mitochondrial deletion syndromes

Substances

Acyl-CoA Dehydrogenase, Long-ChainDNA, Mitochondrial

Authors and institutions

  • Division of Pediatric Hematology and Oncology, The Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel Hashomer, Israel.
  • Faculty of Medicinal and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
  • The Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel Hashomer, Israel.
  • Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Division of Pathology, Sheba Medical Center, Tel Hashomer, Israel.
  • Stem Cell Processing Laboratory, Sheba Medical Center, Tel Hashomer, Israel.

ORCID profiles: Noa Greenberg-Kushnir, Liron D Grossmann, Assaf Arie Barg, Bella Bielorai, Elad Jacoby

Cite

APA

Greenberg-Kushnir, N., Grossmann, L. D., Barg, A. A., Schiby, G., Mardoukh, C., Varda-Bloom, N., Marcu-Malina, V., Anikster, Y., Gruber, N., Lahav, E., Bolkier, Y., Bar, D., Bielorai, B., Toren, A., & Jacoby, E. (2025). Long‐term hematopoietic dysfunction in patients with large‐scale mitochondrial DNA deletion syndromes. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31383

Vancouver

Greenberg-Kushnir N, Grossmann LD, Barg AA, Schiby G, Mardoukh C, Varda-Bloom N, et al. Long‐term hematopoietic dysfunction in patients with large‐scale mitochondrial DNA deletion syndromes. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31383

BibTeX
@article{GreenbergKushnir2025,
  author = {Greenberg-Kushnir, Noa and Grossmann, Liron D and Barg, Assaf Arie and Schiby, Ginnete and Mardoukh, Corine and Varda-Bloom, Nira and Marcu-Malina, Victoria and Anikster, Yair and Gruber, Noah and Lahav, Einat and Bolkier, Yoav and Bar, Diana and Bielorai, Bella and Toren, Amos and Jacoby, Elad},
  title = {Long‐term hematopoietic dysfunction in patients with large‐scale mitochondrial DNA deletion syndromes},
  journal = {Pediatric Blood & Cancer},
  year = {2025},
  doi = {10.1002/pbc.31383}
}
Start for free →